Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H12N4O2 |
Molecular Weight | 232.2386 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)NNC1=C2C=CC=CC2=CN=N1
InChI
InChIKey=WGZDBVOTUVNQFP-UHFFFAOYSA-N
InChI=1S/C11H12N4O2/c1-2-17-11(16)15-14-10-9-6-4-3-5-8(9)7-12-13-10/h3-7H,2H2,1H3,(H,13,14)(H,15,16)
Molecular Formula | C11H12N4O2 |
Molecular Weight | 232.2386 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: www.drugfuture.com/mt/tocoferil-nicotinate.pdfCurator's Comment: description was created based on several sources, including:
http://www.ncbi.nlm.nih.gov/pubmed/6425526
http://www.naoru.com/Apiracohl.html
http://www.ncbi.nlm.nih.gov/pubmed/9412993
Sources: www.drugfuture.com/mt/tocoferil-nicotinate.pdf
Curator's Comment: description was created based on several sources, including:
http://www.ncbi.nlm.nih.gov/pubmed/6425526
http://www.naoru.com/Apiracohl.html
http://www.ncbi.nlm.nih.gov/pubmed/9412993
Todralazine is a hydralazinophthalazine-derived drug currently used in the treatment of arterial hypertension. As vasodilator, it might be used in combination with isosorbide dinitrate. Side effects and drug toxicity were uncommon in such vasodilator therapy.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095216 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2169725 |
|||
Target ID: GO:0016573 Sources: http://www.ncbi.nlm.nih.gov/pubmed/17156885 |
|||
Target ID: CHEMBL2608 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3266791 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseTodralazine is used as an antihypertensive agent |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.przychodnia.pl/el/leki.php3?lek=339
40 – 120 mg in 3 doses per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10719039
Todralazine (TDR) decreased the free radical level in granulocyte samples. At the highest of the tested TDR concentrations (80 μg/ml), the free radical level was lower by ~40% in the samples where only TDR was present than in the control samples (spontaneous release, without TDR).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:54:56 GMT 2023
by
admin
on
Fri Dec 15 15:54:56 GMT 2023
|
Record UNII |
WEN3K83YKD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3122
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL1079787
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
5501
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
757868
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
2691
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
DTXSID0045048
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
D014032
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
C77080
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
m10930
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000077728
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
WEN3K83YKD
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
SUB11141MIG
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
14679-73-3
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |